查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126653

利什曼原蟲症治療市場：依疾病、藥物和地區分類

Leishmaniasis Treatment Market, By Disease Type, By Drug Type, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 256 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

據估計，2026年利利什曼原蟲症治療市值為1.7億美元，預計2033年將達到3.4億美元。預計從2026年到2033年，該市場將以10.58%的複合年成長率成長。

報告範圍 報告詳情
基準年： 2025 2026年市場規模： 1.7億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
2026年至2033年預測期間的複合年成長率： 10.58% 2033年市場規模預測： 3.4億美元

利什曼原蟲症治療市場正經歷顯著的變革，其主要促進因素包括：地方性流行區利什曼原蟲症曼病患病率的上升、內臟利甚曼病、皮膚利甚曼病和黏膜皮膚利什曼原蟲症病發病率的增加、人們對寄生蟲感染疾病的認知不斷提高以及早期診斷技術的進步、各國政府和國際社會加大疾病控制和根除力度、對新型抗寄生蟲療法研發投入的增加，以及對更安全、更有效、更易獲得的治療方法日益成長的需求。該市場涵蓋多種治療方法，包括銻劑、Amphotericin B製劑、米Paromomycin新、巴龍黴素、噴他脒、唑類藥物、聯合治療以及旨在清除利甚曼原蟲、控制疾病併發症、減少治療相關併發症、預防復發和改善患者預後的新型靶向抗寄生蟲療法。

醫療專業人員、公共衛生機構和感染疾病專家日益重視早期利什曼原蟲症、及時利什曼原蟲症和持續監測，以改善內臟利甚曼病、皮膚利甚曼病和黏膜皮膚利什曼原蟲症病患者的治療效果，預防疾病進展，減少併發症，並支持患者的長期康復。診斷技術、抗寄生蟲藥物製劑、聯合治療以及分子和免疫學方法的進步，提高了疾病的檢出率、治療的準確性和療效，並使所有醫療機構都能進行更有針對性的管理。此外，脂質體兩性Amphotericin B、米替福新、銻劑療法、Paromomycin、噴他脒和聯合治療的廣泛應用，最佳化了治療方案的實施，解決了抗藥性問題，降低了治療相關毒性，提高了患者的依從性，預防了復發，並改善了需要有效利利什曼原蟲症管理的患者的臨床療效。

市場動態

由於利什曼原蟲症流行率不斷上升、地方性流行區疾病負擔日益加重、內臟利甚曼病、皮膚利甚曼病和粘膜皮膚利什曼原蟲症的發病率不斷攀升、人們對早期診斷和治療的認知不斷提高、各國政府和國際社會加大力度控制和根除該疾病，以及抗寄生蟲藥物研發和診斷技術的持續進步，市場呈現顯著成長的成長。市場成長的主要驅動力來自醫療保健專業人員、公共衛生機構、感染疾病專家和治療中心，他們尋求更有效、更便捷的治療方案，以根除利甚曼病、預防疾病進展、減少併發症、降低復發率並改善患者的長期預後。這一趨勢在醫院、專科診所、診斷中心、公共衛生機構和社區醫療機構中尤其明顯。脂質體兩性Amphotericin B、米替福辛、銻劑、Paromomycin、唑類藥物以及聯合治療在現代利甚曼病治療中發揮核心作用，有助於提供標靶治療，同時兼顧疾病類型、寄生蟲種類、地理位置和治療反應的差異。隨著人們越來越重視早期發現、及時介入、治療依從性和以患者為中心的疾病管理，對先進的利利什曼原蟲症治療方案的需求也不斷成長。

先進的抗寄生蟲藥物和聯合治療的應用日益廣泛，推動了市場成長。這主要歸功於脂質體Amphotericin B、口服米替福新、Paromomycin類藥物、銻劑、噴他脒以及旨在提高療效並解決毒性、療程和抗藥性等問題的聯合治療。綜合疾病管理方法，包括改進的診斷檢測、寄生蟲鑑定、治療監測、聯合治療和隨訪護理，能夠最佳化治療方案，改善臨床療效，降低復發和治療失敗的風險，並有助於更好地進行長期疾病管理。

對標靶性強、易於取得且技術驅動型療法的日益重視也推動了市場成長。製藥公司、生技公司、醫療服務提供者、公共衛生機構、研究機構、政府機構和國際疾病管制組織在開發和擴大創新利利什曼原蟲症治療和診斷方案的可及性方面發揮關鍵作用。隨著人們對利什曼原蟲症預防、早期診斷和有效治療的認知不斷提高，預計市場將受益於以下因素：抗寄生蟲藥物研發投入的增加、改良治療方案的推廣、流行地區醫療服務覆蓋範圍的擴大、臨床研究活動的增加、更安全有效的療法的開發，以及更經濟實惠、更方便患者使用且臨床療效更佳的治療方案的推出。

本次調查的主要特點

  • 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
  • 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
  • 本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，對利什曼原蟲症治療市場的主要參與者進行了分析。
  • 本報告提供的見解將使行銷負責人和企業經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
  • 利什曼原蟲症治療市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過利用分析利什曼原蟲症治療市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 影響分析
  • 市場趨勢
  • 主要進展
  • 產品核准
  • 合作關係、併購
  • 監理情勢
  • PEST分析
  • 波特五力分析
  • 流行病學
  • 穩健的管道分析

第4章：利什曼原蟲症治療市場：依疾病類型分類，2021-2033年

  • 皮膚利什曼原蟲症
  • 內臟利甚利什曼原蟲症
  • 黏膜皮膚利什曼原蟲症

第5章：利什曼原蟲症治療市場：依藥物類型分類，2021-2033年

  • 五價銻製劑
  • 抗生素

第6章：利什曼原蟲症治療市場：依地區分類，2021-2033年

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲國家
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 澳洲
    • 韓國
    • 其他亞太國家
  • 中東
    • GCC
    • 以色列
    • 其他中東國家
  • 非洲
    • 北非
    • 中非
    • 南非

第7章 競爭情勢

  • 熱圖分析
  • 市佔率分析
  • 公司簡介
    • Sanofi SA
    • Sequus Pharmaceuticals Inc.
    • Paladin Labs Inc.
    • Enzon Pharmaceuticals Inc.
    • Gland Pharma Limited
    • Lifecare Innovations Private Limited
  • 分析師意見

第8章

  • 參考
  • 調查方法
  • 關於本公司
簡介目錄
Product Code: CMI932

Leishmaniasis Treatment Market is estimated to be valued at USD 170 Mn in 2026 and is expected to reach USD 340 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.58% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 170 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 10.58% 2033 Value Projection: USD 340 Mn

The Leishmaniasis Treatment Market is undergoing significant transformation, primarily driven by the rising prevalence of leishmaniasis in endemic regions, increasing incidence of visceral, cutaneous, and mucocutaneous leishmaniasis, growing awareness and early diagnosis of parasitic infections, increasing government and international initiatives for disease control and elimination, rising investments in research and development of novel antiparasitic therapies, and growing demand for safer, more effective, and accessible treatment options. The market includes a wide range of therapeutic approaches, such as antimonials, amphotericin B formulations, miltefosine, paromomycin, pentamidine, azole-based therapies, combination therapies, and emerging targeted antiparasitic treatments designed to eliminate Leishmania parasites, manage disease symptoms, reduce treatment-related complications, prevent relapse, and improve patient outcomes.

Healthcare providers, public health organizations, and infectious disease specialists are increasingly focusing on early diagnosis, timely treatment, and continuous monitoring to improve therapeutic outcomes, prevent disease progression, reduce complications, and support long-term recovery among patients affected by visceral, cutaneous, and mucocutaneous leishmaniasis. Advancements in diagnostic technologies, antiparasitic drug formulations, combination therapies, and molecular and immunological approaches are improving disease detection, treatment precision, and therapeutic effectiveness, while supporting more targeted management across healthcare settings. In addition, the growing adoption of liposomal amphotericin B, miltefosine, antimonial therapies, paromomycin, pentamidine, and combination treatment regimens helps optimize treatment delivery, address drug resistance, reduce treatment-related toxicity, improve patient adherence, prevent relapse, and support better clinical outcomes for individuals requiring effective leishmaniasis management.

Market Dynamics

The market is witnessing significant momentum owing to the increasing prevalence of leishmaniasis, growing disease burden in endemic regions, rising incidence of visceral, cutaneous, and mucocutaneous leishmaniasis, increasing awareness regarding early diagnosis and treatment, growing government and international initiatives for disease control and elimination, and continuous advancements in antiparasitic drug development and diagnostic technologies. The market's growth is largely driven by healthcare providers, public health organizations, infectious disease specialists, and treatment centers seeking more effective and accessible therapeutic solutions to eliminate Leishmania parasites, prevent disease progression, reduce complications, minimize relapse, and improve long-term patient outcomes, particularly across hospitals, specialty clinics, diagnostic centers, public health facilities, and community healthcare settings. Liposomal amphotericin B, miltefosine, antimonial therapies, paromomycin, pentamidine, azole-based treatments, and combination therapies play a central role in modern leishmaniasis management, helping provide targeted treatment while addressing variations in disease type, parasite species, geographic location, and treatment response. The increasing focus on early detection, timely intervention, treatment adherence, and patient-centered disease management is further strengthening the demand for advanced Leishmaniasis treatment solutions.

The expansion of advanced antiparasitic therapies and combination treatment approaches is fueling market growth. This is mainly driven by the increasing adoption of liposomal amphotericin B, oral miltefosine, paromomycin-based regimens, antimonial drugs, pentamidine, and combination therapies designed to improve treatment efficacy and address challenges associated with toxicity, treatment duration, and drug resistance. Integrated disease-management approaches involving improved diagnostic testing, parasite identification, therapeutic monitoring, combination drug regimens, and follow-up care help optimize treatment delivery, improve clinical outcomes, reduce the risk of relapse and treatment failure, and support better long-term disease management.

The growing emphasis on targeted, accessible, and technology-enabled treatment is also propelling the market. Pharmaceutical companies, biotechnology companies, healthcare providers, public health organizations, research institutions, government agencies, and international disease-control organizations play a crucial role in developing and expanding access to innovative leishmaniasis therapies and diagnostic solutions. As awareness of leishmaniasis prevention, early diagnosis, and effective treatment continues to grow, the market is expected to benefit from increased investment in antiparasitic drug research and development, broader adoption of improved treatment regimens, expansion of healthcare access in endemic regions, increasing clinical research activities, development of treatments with improved safety and efficacy profiles, and the introduction of more affordable, patient-friendly, and clinically effective therapeutic solutions.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Leishmaniasis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations Private Limited.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Leishmaniasis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Leishmaniasis treatment Market

Market Segmentation

  • By Disease Type (Revenue, USD Mn, 2021-2033)
  • Cutaneous leishmaniasis
  • Visceral leishmaniasis
  • Mucocutaneous leishmaniasis
  • By Drug Type (Revenue, USD Mn, 2021-2033)
  • Pentavalent antimonials
    • Sodium stibogluconate
    • SSG Meglumine antimoniate
  • Antibiotics
    • Amphotericin B
    • Liposomal amphotericin B
    • Miltefosine
    • Paromomycin
    • Pentamidine
  • By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Key Players Insights
  • Sanofi S.A.
  • Sequus Pharmaceuticals Inc.
  • Paladin Labs Inc.
  • Enzon Pharmaceuticals Inc.
  • Gland Pharma Limited
  • Lifecare Innovations Private Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Approval
  • Collaboration/Merge/Acquisition
  • Regulatory Landscape
  • PEST Analysis
  • Porter's Five Forces Analysis
  • Epidemiology
  • Robust Pipeline Analysis

4. Leishmaniasis Treatment Market, By Disease Type, 2021 - 2033, (USD Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022- 2033
    • Segment Trends
  • Cutaneous leishmaniasis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Visceral leishmaniasis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
  • Mucocutaneous leishmaniasis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. Leishmaniasis Treatment Market, By Drug Type, 2021 - 2033, (USD Million)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Pentavalent antimonials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
      • Sodium stibogluconate
      • SSG Meglumine antimoniate
  • Antibiotics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
      • Amphotericin B
      • Liposomal amphotericin B
      • Miltefosine
      • Paromomycin
      • Pentamidine

6. Leishmaniasis Treatment Market, By Region, 2021 - 2033, (USD Million)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Regions, 2022-2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
      • North Africa
      • Central Africa
      • South Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profile
    • Sanofi S.A.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Sequus Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Paladin Labs Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Enzon Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Gland Pharma Limited
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
    • Lifecare Innovations Private Limited
      • Company Highlights
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Market Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us